We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Clearmind will get exclusive global rights to develop, research, manufacture, and market products derived from psychedelic compounds, which will enhance the company’s portfolio in addiction and mental health treatments
In both the late-stage trials, the drug reduced the AHI against the
The results of the final trial showed that Shingrix is effective against
Under the collaboration, A*STAR will offer its iPSC banks, specialised monoclonal antibody
ReadyGo Diagnostics initiates volume manufacturing of its sample collection and preparation device
